These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 31579608)
1. Brodifacoum does not modulate human cannabinoid receptor-mediated hyperpolarization of AtT20 cells or inhibition of adenylyl cyclase in HEK 293 cells. Sachdev S; Boyd R; Grimsey NL; Santiago M; Connor M PeerJ; 2019; 7():e7733. PubMed ID: 31579608 [TBL] [Abstract][Full Text] [Related]
2. Absence of Entourage: Terpenoids Commonly Found in Santiago M; Sachdev S; Arnold JC; McGregor IS; Connor M Cannabis Cannabinoid Res; 2019; 4(3):165-176. PubMed ID: 31559333 [No Abstract] [Full Text] [Related]
3. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572 [TBL] [Abstract][Full Text] [Related]
4. Cannabichromene is a cannabinoid CB Udoh M; Santiago M; Devenish S; McGregor IS; Connor M Br J Pharmacol; 2019 Dec; 176(23):4537-4547. PubMed ID: 31368508 [TBL] [Abstract][Full Text] [Related]
5. A real time screening assay for cannabinoid CB1 receptor-mediated signaling. Andersen HK; Piroli GG; Walsh KB J Pharmacol Toxicol Methods; 2018; 94(Pt 1):44-49. PubMed ID: 29730318 [TBL] [Abstract][Full Text] [Related]
6. Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene. Udoh M; Santiago M; Haneef S; Rodger A; Marlowe CK; Barr PJ; Connor M Cannabis Cannabinoid Res; 2024 Aug; ():. PubMed ID: 39137108 [No Abstract] [Full Text] [Related]
8. Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors. Ross RA; Gibson TM; Stevenson LA; Saha B; Crocker P; Razdan RK; Pertwee RG Br J Pharmacol; 1999 Oct; 128(3):735-43. PubMed ID: 10516656 [TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350 [TBL] [Abstract][Full Text] [Related]
10. Similarities and differences upon binding of naturally occurring Δ Raïch I; Rivas-Santisteban R; Lillo A; Lillo J; Reyes-Resina I; Nadal X; Ferreiro-Vera C; de Medina VS; Majellaro M; Sotelo E; Navarro G; Franco R Pharmacol Res; 2021 Dec; 174():105970. PubMed ID: 34758399 [TBL] [Abstract][Full Text] [Related]
11. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624 [TBL] [Abstract][Full Text] [Related]
13. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship. Rao GK; Kaminski NE J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563 [TBL] [Abstract][Full Text] [Related]
15. The effects of beta-arrestin1 deletion on acute cannabinoid activity, brain cannabinoid receptors and tolerance to cannabinoids in mice. Breivogel CS; Vaghela MS J Recept Signal Transduct Res; 2015 Feb; 35(1):98-106. PubMed ID: 25779032 [TBL] [Abstract][Full Text] [Related]
16. In vitro determination of the efficacy of illicit synthetic cannabinoids at CB Sachdev S; Vemuri K; Banister SD; Longworth M; Kassiou M; Santiago M; Makriyannis A; Connor M Br J Pharmacol; 2019 Dec; 176(24):4653-4665. PubMed ID: 31412133 [TBL] [Abstract][Full Text] [Related]
17. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal. Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387 [TBL] [Abstract][Full Text] [Related]
18. Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors. Redmond WJ; Cawston EE; Grimsey NL; Stuart J; Edington AR; Glass M; Connor M Br J Pharmacol; 2016 Jan; 173(1):115-27. PubMed ID: 26398720 [TBL] [Abstract][Full Text] [Related]
19. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Kaminski NE; Koh WS; Yang KH; Lee M; Kessler FK Biochem Pharmacol; 1994 Nov; 48(10):1899-908. PubMed ID: 7986201 [TBL] [Abstract][Full Text] [Related]
20. (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. Bayewitch M; Rhee MH; Avidor-Reiss T; Breuer A; Mechoulam R; Vogel Z J Biol Chem; 1996 Apr; 271(17):9902-5. PubMed ID: 8626625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]